Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2021, at 11:45 a.m. (ET). The presentation will highlight the company's innovative approach to treating non-alcoholic steatohepatitis (NASH) with its investigational drug, efruxifermin (EFX). EFX aims to offer potential benefits as a best-in-class medicine, with ongoing Phase 2b trials evaluating its effectiveness in patients with varying fibrosis stages. A live webcast of the presentation will be available on Akero's investor relations website.

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET).

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero’s investigational drug product candidate, efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of effects observed in clinical studies position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in pre-cirrhotic patients with F2/F3 fibrosis and the SYMMETRY study in cirrhotic (F4) patients. Akero is headquartered in South San Francisco. Visit www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
650.487.6488
media@akerotx.com

FAQ

When will Akero Therapeutics present at the Morgan Stanley Virtual Global Healthcare Conference?

Akero Therapeutics will present on September 15, 2021, at 11:45 a.m. (ET).

What is the focus of Akero Therapeutics' presentation at the Morgan Stanley conference?

The presentation will focus on the company's treatments for non-alcoholic steatohepatitis (NASH) and their investigational drug efruxifermin (EFX).

Where can I watch the Akero Therapeutics conference presentation?

The live webcast of the presentation will be available on Akero Therapeutics' investor relations website.

What is efruxifermin (EFX) being developed for by Akero Therapeutics?

Efruxifermin (EFX) is being developed as a treatment for non-alcoholic steatohepatitis (NASH).

What clinical trials is efruxifermin (EFX) currently undergoing?

Efruxifermin (EFX) is currently being evaluated in two Phase 2b clinical trials: the HARMONY study and the SYMMETRY study.